MedTrace Logo

The Role of the Muscle-nervous System Interface in Cancer Cachexia

NCT03477721 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 40

Last updated 2018-03-26

No results posted yet for this study

Summary

Sarcopenia is an important component of cachexia associated with cancer, and their high incidence in cancer patients emphasizes the need for a better understanding of its mechanisms, which can result in better therapeutic interventions to reverse this situation and improve the prognosis. Our hypothesis is that the plasma concentration of IL-6 and c-terminal agrin is directly correlated with the loss of muscle mass and development of cachexia.

Conditions

  • Cachexia; Cancer; Sarcopenia

Sponsors & Collaborators

  • University of Roma La Sapienza

    lead OTHER

Principal Investigators

  • Alessandro Laviano, MD · Department of Clinical Medicine, Sapienza University of Rome, Italy

Eligibility

Min Age
18 Years
Max Age
100 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-03-16
Primary Completion
2018-04-16
Completion
2018-04-30

Countries

  • Italy

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03477721 on ClinicalTrials.gov